<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05008614</url>
  </required_header>
  <id_info>
    <org_study_id>2104-142-1214</org_study_id>
    <nct_id>NCT05008614</nct_id>
  </id_info>
  <brief_title>Comparison of Continuous ESP Versus TEA After Thoracotomy</brief_title>
  <official_title>Continuous Erector Spinae Plane Block Versus Thoracic Epidural Analgesia After Thoracotomy: A Randomized Controlled Assessor-blinded Non-inferiority Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Seoul National University Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Seoul National University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Seoul National University Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This prospective, randomized, assessor-blinded study is designed to evaluate the&#xD;
      postoperative analgesic efficacy of the ultrasound-guided continuous erector spinae plane&#xD;
      (ESP) block in patients undergoing thoracotomy. We hypothesize that US-guided ESP block is&#xD;
      not inferior to thoracic epidural analgesia in terms of postoperative pain control in these&#xD;
      patients.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Adult patients undergoing elective unilateral thoracotomy for lung cancer resection are&#xD;
      randomly allocated to receive US-guided ESP block (n=31) or thoracic epidural analgesia&#xD;
      (n=31). Both procedures are performed prior to surgery. Each patient was assessed by a&#xD;
      blinded investigator on postoperative day (POD) 1,2 and 3. The primary outcome is pain&#xD;
      severity evaluated by a numeric rating scale (NRS) at POD1.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">July 22, 2021</start_date>
  <completion_date type="Anticipated">July 16, 2023</completion_date>
  <primary_completion_date type="Anticipated">May 16, 2023</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>A prospective randomized controlled assessor-blinded non-inferiority trial</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Outcomes Assessor)</masking>
    <masking_description>The outcome assessor not involved in this study will investigate the outcomes.</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Maximum postoperative pain score at rest on postoperative day 1</measure>
    <time_frame>Maximum pain score among the 9 am and 4 pm measurements on postoperative day 1</time_frame>
    <description>pain score measured by the 11-pointed numeric rating scale (0: none/10: worst pain)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Postoperative pain score at rest</measure>
    <time_frame>9am/4pm on postoperative day 1, 9am/4pm on postoperative day 2, 9am/4pm on postoperative day 3</time_frame>
    <description>Change in the pain score at rest measured by the 11-pointed numeric rating scale (0: none/10: worst pain) from postoperative day 1 to postoperative day 3</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Postoperative pain score at movement</measure>
    <time_frame>9am/4pm on postoperative day 1, 9am/4pm on postoperative day 2, 9am/4pm on postoperative day 3</time_frame>
    <description>Change in the pain score at movement measured by the 11-pointed numeric rating scale (0: none/10: worst pain) from postoperative day 1 to postoperative day 3</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in the total consumption (ml) of patient-controlled analgesia</measure>
    <time_frame>9am/4pm on postoperative day 1, 9am/4pm on postoperative day 2, 9am/4pm on postoperative day 3</time_frame>
    <description>total consumption (ml) of epidural or erector spinae plane patient-controlled analgesia</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in the quality of recovery-15 scale from baseline to postoperative day 3</measure>
    <time_frame>Day before surgery and 4pm on postoperative day 3</time_frame>
    <description>measured by the Korean version of the quality of recovery-15</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Postoperative pulmonary function test</measure>
    <time_frame>3 months after surgery</time_frame>
    <description>measured at outpatient clinic</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of chronic postoperative pain</measure>
    <time_frame>3 months after surgery</time_frame>
    <description>measure by the Korean version of the pain DETECT</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of chronic postoperative pain</measure>
    <time_frame>6 months after surgery</time_frame>
    <description>measure by the Korean version of the pain DETECT</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">62</enrollment>
  <condition>Postoperative Pain</condition>
  <arm_group>
    <arm_group_label>Erector spinae plane block group (ESP group)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients receiving continuous unilateral ESP block.&#xD;
Interventions:&#xD;
Procedure: Ultrasound-guided unilateral ESP block via catheter placement for continuous infusion Drug: Ropivacaine 0.75% Injectable Solution Device: 21-gauge 85 mm perineural catheter, 18-gauge 100 mm stimulator needle (Silverstim, Vygon, Ecouen, France)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Thoracic epidural analgesia group (TEA group)</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Patients receiving thoracic epidural analgesia.&#xD;
Interventions:&#xD;
Procedure: Fluoroscopy-guided thoracic epidural analgesia Drug: Ropivacaine 0.75% Injectable Solution Device: 17-gauge Tuohy needle (FlexTip Plus®, Teleflex Medical, USA)</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Erector spinae plane block group</intervention_name>
    <description>Before surgery, an anesthesiologist will perform unilateral ESP block with catheterization under ultrasound guidance in the procedure room.&#xD;
Drug: Ropivacaine 0.75% Injectable Solution 0.2% ropivacaine is continuously infused to the erector spinae plane at T5 level via 18G 85 mm perineural catheter (Silverstim, Vygon, Ecouen, France) (basal infusion: 10ml/hr, bolus 5ml, lockout time: 20min)</description>
    <arm_group_label>Erector spinae plane block group (ESP group)</arm_group_label>
    <other_name>ESP group</other_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Thoracic epidural analgesia group</intervention_name>
    <description>Before surgery, an anesthesiologist will perform unilateral ESP block with catheterization under fluoroscopy guidance in the procedure room.&#xD;
Drug: Ropivacaine 0.75% Injectable Solution 0.2% ropivacaine is continuously infused to the erector spinae plane at T5 level via 17-gauge catheter (FlexTip Plus®, Teleflex Medical, USA) (Silverstim, Vygon, Ecouen, France) (basal infusion: 3ml/hr, bolus 1ml, lockout time: 20min)</description>
    <arm_group_label>Thoracic epidural analgesia group (TEA group)</arm_group_label>
    <other_name>TEA group</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Patients scheduled to undergo elective thoracotomy for lung cancer&#xD;
&#xD;
          -  European Cooperative Oncology Group 0 or 1&#xD;
&#xD;
          -  American Society of Anesthesiologists (ASA) physical classification I-III&#xD;
&#xD;
          -  Willingness and ability to sign an informed consent document&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  patients with chronic postoperative pain after thoracic surgery&#xD;
&#xD;
          -  patients undergoing thoracotomy with chest wall resection&#xD;
&#xD;
          -  allergies to anesthetic or analgesic medications&#xD;
&#xD;
          -  patients with coagulopathy or who continue to take anticoagulants&#xD;
&#xD;
          -  preoperative liver or renal dysfunction&#xD;
&#xD;
          -  patients with chronic pain, chronic opioid, analgesic or antidepressant or&#xD;
             anticonvulsant use&#xD;
&#xD;
          -  Do not understand our study&#xD;
&#xD;
          -  Medical or psychological disease that can affect the treatment response&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Hojin Lee, MD</last_name>
    <phone>82-2-2072-0039</phone>
    <email>zenerdiode03@gmail.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Susie Yoon, MD, PhD</last_name>
    <phone>82-2-2072-2467</phone>
    <email>susiey87@gmail.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Seoul National University Hospital</name>
      <address>
        <city>Seoul</city>
        <zip>KS013</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Hojin Lee, MD</last_name>
      <phone>82-2-2072-2467</phone>
      <email>zenerdiode03@gmail.com</email>
    </contact>
    <contact_backup>
      <last_name>Susie Yoon, MD, PhD</last_name>
      <phone>82-2-2072-2467</phone>
      <email>susiey87@gmail.com</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>August 2021</verification_date>
  <study_first_submitted>August 3, 2021</study_first_submitted>
  <study_first_submitted_qc>August 9, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">August 17, 2021</study_first_posted>
  <last_update_submitted>August 9, 2021</last_update_submitted>
  <last_update_submitted_qc>August 9, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">August 17, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Seoul National University Hospital</investigator_affiliation>
    <investigator_full_name>Susie Yoon</investigator_full_name>
    <investigator_title>Assistant clinical professor</investigator_title>
  </responsible_party>
  <keyword>thoracotomy</keyword>
  <keyword>lung cancer</keyword>
  <keyword>interfascial plane block</keyword>
  <keyword>nerve block</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pain, Postoperative</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

